Primarily based on knowledge, 1.75 mg/kg dose established as really helpful dose for Part 3 trial of this investigational antibody-drug conjugate
RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), often called MSD outdoors of america and Canada, as we speak introduced the primary presentation of information from the Part 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck (NS:)’s investigational antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), together with cyclophosphamide, doxorubicin and prednisone plus rituximab (R-CHP) for the therapy of sufferers with beforehand untreated diffuse massive B-cell lymphoma (DLBCL). At a pre-planned evaluation, zilovertamab vedotin together with R-CHP achieved a 100% (n=15) full response (CR) charge in sufferers handled with zilovertamab vedotin at 1.75 mg/kg. Primarily based on the info, the research has established 1.75 mg/kg because the really helpful Part 3 dose of zilovertamab vedotin. These knowledge are being offered for the primary time as we speak in an oral presentation (Summary #578) on the 66th American Society of Hematology (ASH) Annual Assembly and Exposition.
There’s a want for added first-line therapy choices to assist sufferers with diffuse massive B-cell lymphoma, since, sadly, roughly 40% nonetheless expertise relapsed or refractory illness after preliminary therapy with the present customary of care, mentioned Dr. Muhit Ozcan, the research’s principal investigator, Ankara College College of Medication. These knowledge from the Part 2 waveLINE-007 trial are promising and assist additional analysis within the first-line setting in a bigger affected person inhabitants to assist deal with this vital unmet want for sufferers.
We’re happy to see these early constructive outcomes from the Part 2 waveLINE-007 trial, through which zilovertamab vedotin demonstrated a extremely promising response charge and a manageable security profile together with customary of care, mentioned Dr. Gregory Lubiniecki, vp, oncology medical analysis, Merck Analysis Laboratories. We sit up for advancing our analysis of this investigational ROR1-directed antibody drug conjugate, which we imagine has sturdy potential in a number of hematologic malignancies.
As introduced, knowledge from greater than 20 abstracts are being offered from throughout a broad vary of hematologic malignancies from Merck’s hematology pipeline, which features a various vary of investigational property with novel modalities, on the 66th ASH Annual Assembly and Exposition.
Examine design and extra knowledge from waveLINE-007
WaveLINE-007 is a non-randomized, open-label Part 2 trial (ClinicalTrials.gov, NCT05406401) evaluating zilovertamab vedotin (MK-2140) together with R-CHP in sufferers with beforehand untreated DLBCL. The first endpoints are security (variety of sufferers with dose limiting toxicity, hostile occasions and discontinuation as a result of hostile occasions) and CR charge based mostly on investigator assessment per Lugano Response Standards. Secondary endpoints embrace goal response charge (ORR) and period of response (DOR) per Lugano Response Standards. As of information cut-off, 36 sufferers have been enrolled within the research to obtain zilovertamab vedotin plus R-CHP intravenously on day 1 of every 21-day cycle (Q3W) for as much as eight cycles. The therapy arms of the research included:
- 1.75 mg/kg (n=15); all 15 sufferers on this arm accomplished the trial (none discontinued)
- 2.0 mg/kg (n=15); 14 sufferers on this arm accomplished therapy and one affected person discontinued after cycle 1 as a result of doctor resolution and was entered to security follow-up, or
- 2.25 mg/kg (n=6); 5 sufferers on this arm accomplished therapy and one affected person discontinued as a result of doctor resolution
The efficacy outcomes confirmed a CR was achieved together with R-CHP in 100% (n=15) of sufferers receiving the 1.75 mg/kg dose of zilovertamab vedotin (CI: 95%, 78.2-100.0), 93.3% (n=14) of sufferers receiving the two.0 mg/kg dose (CI: 95%, 68.1-99.8) and 100% (n=6) of sufferers receiving the two.25 mg/kg dose (CI: 95%, 54.1-100.0). The overall CR charge on the finish of therapy was 97.2% (CI: 95%, 85.5-99.9). The median follow-up for all sufferers was 17.6 months (vary, 7.1-24.6). The ORR was 100% (CI: 95%, 78.2-100.0) for sufferers receiving the 1.75 mg/kg dose, 93.3% (CI: 95%, 68.1-99.8) for sufferers receiving the two.0 mg/kg dose, and 100% (CI: 95%, 54.1-100.0) for sufferers receiving the two.25 mg/kg dose, all together with R-CHP. The median DOR has not been reached for all sufferers, and the overall 12-month DOR was 93.5%. Primarily based on the info, the really helpful zilovertamab vedotin dose was decided to be 1.75 mg/kg.
Severe treatment-related hostile occasions (TRAEs) occurred in 11% (n=4) of all sufferers (1.75 mg/kg [n=1], 2.0 mg/kg [n=1], 2.25 mg/kg [n=2]). Grade 3-4 TRAEs occurred in 58% (n=21) of all sufferers. The most typical of those occasions have been neutropenia, nausea, anemia and diarrhea.
About diffuse massive B-cell lymphoma
Lymphoma is most cancers starting within the lymphatic system “ the community of organs, vessels and tissues that protects the physique from an infection. There are lots of subtypes of lymphoma, which are sometimes categorized into two predominant varieties “ Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). DLBCL, the commonest type of NHL, is derived from white blood cells that develop quickly and uncontrollably, enlarging the lymph nodes and infrequently migrating to different components of the physique. DLBCL accounts for about 25-30% of all non-Hodgkin lymphomas worldwide. Within the U.S., it’s estimated that roughly 25,000 sufferers are recognized with DLBCL every year. The five-year relative survival charge for DLBCL is 60-70%.
About zilovertamab vedotin (MK-2140)
Zilovertamab vedotin is an investigational ADC that targets ROR1. ROR1 is a transmembrane protein that’s overexpressed in a number of hematologic malignancies. Merck is dedicated to analysis with zilovertamab vedotin throughout B-cell malignancies and is establishing a strong program of medical trials below the title waveLINE. The waveLINE program features a Part 2/3 research in sufferers with relapsed or refractory DLBCL (waveLINE-003, NCT05139017) and a Part 3 research in therapy naïve sufferers with DLBCL (waveLINE-010, NCT06717347).
About Merck in hematology
Merck is dedicated to advancing innovation and take care of folks with hematologic neoplasms and malignancies. Constructing on its management in oncology, the corporate has a broad medical improvement program that evaluates novel mechanisms of motion to handle longstanding unmet wants for sufferers with hematologic problems. Amongst Merck’s analysis efforts are research evaluating a number of investigational medicines as monotherapy or together with different therapies throughout a variety of hematologic neoplasms and malignancies.
Merck’s give attention to most cancers
Every single day, we comply with the science as we work to find improvements that may assist sufferers, it doesn’t matter what stage of most cancers they’ve. As a number one oncology firm, we’re pursuing analysis the place scientific alternative and medical want converge, underpinned by our various pipeline of greater than 25 novel mechanisms. With one of many largest medical improvement applications throughout greater than 30 tumor varieties, we try to advance breakthrough science that may form the way forward for oncology. By addressing boundaries to medical trial participation, screening and therapy, we work with urgency to cut back disparities and assist guarantee sufferers have entry to high-quality most cancers care. Our unwavering dedication is what is going to carry us nearer to our objective of bringing life to extra sufferers with most cancers. For extra info, go to https://www.merck.com/analysis/oncology.
About Merck
At Merck, often called MSD outdoors of america and Canada, we’re unified round our function: We use the ability of modern science to avoid wasting and enhance lives around the globe. For greater than 130 years, we’ve got introduced hope to humanity via the event of essential medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical firm on the planet “ and as we speak, we’re on the forefront of analysis to ship progressive well being options that advance the prevention and therapy of illnesses in folks and animals. We foster a various and inclusive world workforce and function responsibly on daily basis to allow a secure, sustainable and wholesome future for all folks and communities. For extra info, go to www.merck.com and join with us on X (previously Twitter), Fb (NASDAQ:), Instagram, YouTube and LinkedIn.
Ahead-Wanting Assertion of Merck & Co., Inc., Rahway, N.J., USA
This information launch of Merck & Co., Inc., Rahway, N.J., USA (the corporate) contains forward-looking statements inside the which means of the secure harbor provisions of the U.S. Non-public Securities Litigation Reform Act of 1995. These statements are based mostly upon the present beliefs and expectations of the corporate’s administration and are topic to vital dangers and uncertainties. There will be no ensures with respect to pipeline candidates that the candidates will obtain the mandatory regulatory approvals or that they may show to be commercially profitable. If underlying assumptions show inaccurate or dangers or uncertainties materialize, precise outcomes might differ materially from these set forth within the forward-looking statements.
Dangers and uncertainties embrace however should not restricted to, common trade circumstances and competitors; common financial elements, together with rate of interest and foreign money alternate charge fluctuations; the affect of pharmaceutical trade regulation and well being care laws in america and internationally; world traits towards well being care price containment; technological advances, new merchandise and patents attained by opponents; challenges inherent in new product improvement, together with acquiring regulatory approval; the corporate’s skill to precisely predict future market circumstances; manufacturing difficulties or delays; monetary instability of worldwide economies and sovereign threat; dependence on the effectiveness of the corporate’s patents and different protections for innovation merchandise; and the publicity to litigation, together with patent litigation, and/or regulatory actions.
The corporate undertakes no obligation to publicly replace any forward-looking assertion, whether or not on account of new info, future occasions or in any other case. Further elements that might trigger outcomes to vary materially from these described within the forward-looking statements will be discovered within the firm’s Annual Report on Kind 10-Okay for the 12 months ended December 31, 2023 and the corporate’s different filings with the Securities and Change Fee (SEC) accessible on the SEC’s Web website (www.sec.gov).
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20241208871516/en/
Media:
Julie Cunningham, (617) 519-6264
Sienna Choi, (908) 873-4311
Investor:
Peter Dannenbaum, (732) 594-1579
Steven Graziano, (732) 594-1583
Supply: Merck & Co., Inc.
